LYNPARZA (olaparib), PARP inhibitor

Minor improvement in the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA1- or BRCA2-mutated high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy.

• LYNPARZA has been granted a Marketing Authorisation as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial response) to platinum-based chemotherapy.
• Its efficacy as a maintenance treatment of BRCA1- or BRCA2-mutated ovarian cancer has been demonstrated versus placebo in terms of progression-free survival, though with no demonstrated impact on overall survival.